文献速递肝病

铜蓝蛋白基因变异与非酒精性脂肪性肝病高铁蛋白血症及肝铁增加相关

Ceruloplasmin gene variants are associated with hyperferritinemia and increased liver iron in patients with NAFLD.
PubMed 文献 · J Hepatol · 2021-03-24

该研究从328例组织学诊断NAFLD的意大利队列中选取高铁蛋白血症伴铁染色阳性者23例及正常对照25例,对32个铁代谢相关基因重测序,发现铜蓝蛋白变异与高铁蛋白血症、肝铁沉积及更严重肝纤维化独立相关,总体队列中调整OR为5.99(95%CI 1.83-19.60,p=0.0009)。

要点

  • NAFLD患者中非HFE铁基因罕见致病变异与高铁蛋白血症及肝铁沉积相关。
  • 铜蓝蛋白是最常见突变基因,其变异独立关联高铁蛋白血症与更严重肝纤维化。
  • 总体队列中铜蓝蛋白变异与高铁蛋白血症的调整OR为5.99(95%CI 1.83-19.60)。

核心结论

  • 非HFE铁基因变异,尤其铜蓝蛋白变异,与NAFLD患者高铁蛋白血症和肝铁增加相关。
  • 携带此类变异者肝纤维化更严重,提示遗传性肝铁沉积倾向可能促进肝病进展。

研究设计与样本

  • 从328例组织学诊断NAFLD的意大利队列中选取高铁蛋白血症(铁蛋白>750 ng/ml)且铁染色阳性者23例,以及铁蛋白正常且铁染色阴性对照25例。
  • 排除转铁蛋白饱和度升高、贫血、炎症、β-地中海贫血特质、HFE基因型铁过载风险及ferroportin突变者。
  • 对32个铁相关基因进行重测序,结合文献与计算机预测对致病突变进行优先级排序。

主要发现

  • 高铁蛋白血症组潜在致病罕见变异患病率高于对照组(73.9% vs. 20%,p=0.0002)。
  • 这些变异与更高铁储备及更严重肝纤维化相关(p<0.05)。
  • 铜蓝蛋白是最常见突变基因,其变异独立关联高铁蛋白血症、肝铁沉积及更严重肝纤维化(p<0.05)。
  • 在总体队列中,铜蓝蛋白变异独立关联高铁蛋白血症(调整OR 5.99;95%CI 1.83-19.60;p=0.0009)。

关键数值与推荐

  • 高铁蛋白血症定义为铁蛋白>750 ng/ml且铁染色阳性。
  • 铜蓝蛋白变异与高铁蛋白血症的调整OR为5.99(95%CI 1.83-19.60;p=0.0009)。

临床怎么用

  • 对NAFLD合并高铁蛋白血症及肝铁沉积者,可考虑评估非HFE铁基因(尤其铜蓝蛋白)变异。
  • 携带铜蓝蛋白等铁基因变异者肝纤维化风险更高,需加强肝病严重度监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Non-alcoholic fatty liver disease (NAFLD) is a multifactorial disorder resulting from genetic and environmental factors. Hyperferritinemia has been associated with increased hepatic iron stores and worse outcomes in patients with NAFLD. The aim of this study was to evaluate the prevalence of variants of iron-related genes and their association with hyperferritinemia, hepatic iron stores and liver disease severity in patients with NAFLD. METHODS: From a cohort of 328 individuals with histological NAFLD, 23 patients with ferritin >750 ng/ml and positive iron staining, and 25 controls with normal ferritin and negative iron staining, were selected. Patients with increased transferrin saturation, anemia, inflammation, β-thalassemia trait, HFE genotype at risk of iron overload and ferroportin mutations were excluded. A panel of 32 iron genes was re-sequenced. Literature and in silico predictions were employed for prioritization of pathogenic mutations. RESULTS: Patients with hyperferritinemia had a higher prevalence of potentially pathogenic rare variants (73.9% vs. 20%, p = 0.0002) associated with higher iron stores and more severe liver fibrosis (p <0.05). Ceruloplasmin was the most mutated gene and its variants were independently associated with hyperferritinemia, hepatic siderosis, and more severe liver fibrosis (p <0.05). In the overall cohort, ceruloplasmin variants were independently associated with hyperferritinemia (adjusted odds ratio 5.99; 95% CI 1.83-19.60; p = 0.0009). CONCLUSIONS: Variants in non-HFE iron genes, particularly ceruloplasmin, are associated with hyperferritinemia and increased hepatic iron stores in patients with NAFLD. Carriers of such variants have more severe liver fibrosis, suggesting that genetic predisposition to hepatic iron deposition may translate into liver disease. LAY SUMMARY: Non-alcoholic fatty liver disease (NAFLD) is a common disease which can progress to cirrhosis and liver cancer. Increased levels of serum ferritin are often detected in patients with NAFLD and have been associated with altered iron metabolism and worse patient outcomes. We found that variants of genes related to iron metabolism, particularly ceruloplasmin, are associated with high ferritin levels, hepatic iron deposition and more severe liver disease in an Italian cohort of patients with NAFLD.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Corradini E, Buzzetti E, Dongiovanni P, et al. Ceruloplasmin gene variants are associated with hyperferritinemia and increased liver iron in patients with NAFLD. J Hepatol. 2021. PMID: 33774058. doi:10.1016/j.jhep.2021.03.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。